Skip to main content
OpenTrials
Completed

NCT Number: NCT03421340

Non-Complex Biliary Stones DSC vs ERC

To prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary stone clearance using standard endoscopic retrograde cholangiography (ERC).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Asian Institute of Gastroenterology, Hyderabad, Somajiguda, India

Loading trial locations.

About this study

The objective of this study is to prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary stone clearance using standard endoscopic retrograde cholangioscopy (ERC).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older
  • Abdominal pain consistent with choledocholithiasis (procedure possible within 72 hours of onset of symptoms and imaging suggesting choledocholithiasis, contingent on persistent abdominal pain)
  • Abnormal LFTs
  • Non-complex biliary stone disease, defined as 5 or fewer stones in the common bile or common hepatic duct with largest stone no larger than 10 mm in size. If stones not seen on imaging (US, CT) the bile duct diameter should be ≤12 mm*
  • Given the poor sensitivity (approximately 20%) for biliary stones of CT and US, the diameter of the dilated CBD is used as a surrogate for largest stone diameter
  • Availability of non-invasive imaging to determine the diameter of the bile duct and number and size of bile duct stones if visible on imaging
  • If probability of stones is high per investigator assessment based on ASGE criteria, any standard of practice imaging modality (eg. abdominal US) is acceptable.
  • If the probability of stones is either intermediate or low per investigator assessment based on ASGE criteria, MRCP or EUS imaging is required to confirm presence of stones.
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study

Exclusion criteria

  • Potentially vulnerable subjects, including but not limited to pregnant women and subjects in whom an endoscopic procedure is contraindicated
  • Location of the stones in intrahepatic ducts, cystic duct or proximal to strictures
  • Bile duct stricture noted distal to stone on MRCP, which would make extraction without lithotripsy impossible
  • Ongoing cholangitis at time of randomization, manifested by fever with tachycardia and hypotension or evidence of pus at the ampulla
  • Patients with prior biliary sphincterotomy
  • Patients with Primary Sclerosing Cholangitis (PSC)
  • Acute pancreatitis, defined as abdominal pain and serum concentration of pancreatic enzymes [lipase (required), amylase (optional)] three or more times the upper limit of normal
  • Surgically altered gastro-duodenal luminal anatomy other than prior Billroth I reconstruction, as these would be anticipated to lead to more complicated procedures
  • Coagulopathy or ongoing need for anti-coagulation

Treatment and study plan

DSC

Device

Stone removal without fluoroscopy using the SpyGlass device.

Other names: Direct Solitary Cholangioscopy

ERC

Device

Standard of care stone removal with fluoroscopy.

Other names: Endoscopic Retrograde Cholangiography

Primary outcomes

  1. Number of Participants With Complete Stone Clearance

    Time frame: 30 Days

    Prospectively compare DSC vs. ERC

Secondary outcomes

  1. Rate of Serious Adverse Events

    Time frame: 30 Days

    To evaluate all SAEs including death, severity, onset, time to resolution.

  2. Radiation Exposure

    Time frame: 3 hours

    Total Fluoroscopy time

  3. Duration of Procedure

    Time frame: 3 hours

    Defined as time from duodenoscope in to completion of stone clearance.

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

Prospective, Multi-center, Randomized Controlled Study Comparing Endoscopic Clearance of Non-Complex Biliary Stones Using Fluoroscopy/Radiation-Free Direct Solitary Cholangioscopy (DSC) to Standard of Care Endoscopic Retrograde Cholangiography (ERC)

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Feb 5, 2018
Registry last updated
Jan 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.